Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Auto Immune Disease Clear all
Completed No phase listed Observational

Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases

NCT00357071
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 11, 2026, 11:56 PM EDT
Withdrawn Phase 2 Interventional

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

NCT00230035
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab

NCT02296424
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis (SJIA)
Interventions
ACZ885 150 mg (Canakinumab)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 20 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 11, 2026, 11:56 PM EDT
Recruiting Phase 2 Interventional

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide, Total Body Irradiation
Drug · Procedure · Biological + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 11, 2026, 11:56 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612
View directory record Official record
Conditions
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma
Interventions
AUTO CAR T cell therapy
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 11, 2026, 11:56 PM EDT
Completed No phase listed Observational

The CARRA Registry

NCT01697254
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device

NCT01618955
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
VIBEX MTX
Device
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation

NCT00817752
View directory record Official record
Conditions
Inflammation, Cancer, Autoimmune Diseases
Interventions
Ashwagandha
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Sep 11, 2026, 11:56 PM EDT
Recruiting No phase listed Observational

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

NCT04052022
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 11, 2026, 11:56 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

NCT02041091
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Covina, California • El Cajon, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 11, 2026, 11:56 PM EDT
Terminated Phase 2 Interventional Results available

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

NCT01548573
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 11, 2026, 11:56 PM EDT
Completed No phase listed Observational

Cause, Development, and Progression of Stiff-Person Syndrome

NCT00030940
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

NCT01241708
View directory record Official record
Conditions
Multiple Myeloma, Auto Stem Cell Transplant
Interventions
Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

NCT01241734
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Revlimid
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Hackensack, New Jersey • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 1 Interventional

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

NCT03383055
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma
Interventions
CMV-MVA Triplex Vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 11, 2026, 11:56 PM EDT
Active, not recruiting Phase 2 Interventional

Descartes-08 for Patients With Systemic Lupus Erythematosus

NCT06038474
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Descartes-08
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Redirected Auto T Cells for Advanced Myeloma

NCT01352286
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous Genetically modified T cells
Genetic
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug

NCT03014674
View directory record Official record
Conditions
Asthma
Interventions
Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector, Prefilled Safety Syringe
Biological · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Biological
Lead sponsor
Arthritis & Rheumatic Disease Specialties Research
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 11, 2026, 11:56 PM EDT
Completed No phase listed Observational

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

NCT02652091
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 11, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

NCT05032820
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, bb2121, Cyclophosphamide, Fludarabine, leukapheresis
Drug · Biological · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 11, 2026, 11:56 PM EDT
Terminated Phase 2 Interventional Results available

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

NCT01453088
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
60 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 11, 2026, 11:56 PM EDT